XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > Nasdaq baby here we come!

<< Previous

Bullboard Posts

Next >>

Comment by Johnny6565on Sep 17, 2021 7:31am

104 Views

Post# 33876330

RE:Nasdaq baby here we come!

Providence Gold Mines

Providence News out on monday

PHD was at much higher prices before they discovered the stockpile!
Someone has been constantly pounding on PHD after good news.
Now PHD has the market maker !
The upside is and will really always be their drilling results!
I am looking forward to Monday !

<< Previous

Bullboard Posts

Next >>

Top 10 pharmaceutical AI stocks